东曜药业-B(01875.HK)前三季度营收约为6.22亿元

Core Viewpoint - Dongyao Pharmaceutical-B (01875.HK) reported a significant decline in revenue for the first three quarters of the fiscal year ending September 30, 2025, with a year-on-year decrease of approximately 23.15% [1] Financial Performance - Revenue for the first three quarters was approximately RMB 622 million [1] - The company recorded a net loss of RMB 3.37 million [1]